CSL have an interesting test by the end of March. There is an initial DMC futility review of their CSL112.
The very large Phase IiB n>1000 was less than spectacular in terms of efficacy. Endpoints were not powered for efficacy however CSL are confident on the MOA.
CSL112 is a potential indirect threat tor Revascor (or whatever it is called these days) in that it is meant to reduce those that' go on to CHF due to coronary artery disease.
MSB Trading - 2020, page-1041
-
- There are more pages in this discussion • 22,120 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.045(4.00%) |
Mkt cap ! $1.335B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.980M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 73090 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 27903 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |